Biotech Business - November 18, 2026
Lytix Biopharma raises NOK 80 million
Lytix Biopharma has raised NOK 80 million in a private placement and retail offering to prepare a registrational Phase III study of ruxotemitide in neoadjuvant melanoma.
Biotech Business - November 17, 2026
Commit Biologics raises USD 60 million seed round
Commit Biologics has closed a USD 60 million (EUR 54 million) seed financing to take its first complement-powered immune engager, COM002, toward the clinic.
Biotech Business - November 11, 2026
AAX Biotech and Discovery Evolution team up on bispecific cancer antibodies
AAX Biotech and Discovery Evolution have started a research collaboration to discover and develop bispecific antibody candidates in oncology. The goal is to produce differentiated candidates for further preclinical evaluation.
Biotech article - November 11, 2026
Circio and Solid Biosciences test circular RNA in heart gene therapy
Circio has started a research collaboration with US company Solid Biosciences to evaluate whether combining its circVec circular RNA technology with Solid's AAV capsid, POLARIS-101, can produce more potent and targeted gene therapies for genetic heart disease.
Biotech Business - November 3, 2026
Vitroscope raises USD 7 million to scale up live-tissue platform
Trondheim-based Vitroscope has raised USD 7 million, made up of a USD 5 million seed round co-led by Cerberus Ventures and YZR Capital and USD 2 million in non-dilutive funding from the Research Council of Norway.
Biotech Business - November 3, 2026
Partnership links target discovery and drug design
Rayca Precision, which operates in Helsinki and London, has partnered with Dutch TechBio company QurieGen to offer pharma and biotech R&D teams a joint workflow that connects the discovery of new drug targets with the design and testing of drug candidates.